Updates are available Correction dated 2019-07-16
Click to view Correction: https://doi.org/10.1038/s41586-019-1380-3
-
Authors
Bertucci, François
Ng, Charlotte K. Y.
Patsouris, Anne
Droin, Nathalie
Piscuoglio, Salvatore
Carbuccia, Nadine
Soria, Jean Charles
Dien, Alicia Tran
Adnani, Yahia
Kamal, Maud
Garnier, Séverine
Meurice, Guillaume
Jimenez, Marta
Dogan, Semih
Verret, Benjamin
Chaffanet, Max
Bachelot, Thomas
Campone, Mario
Lefeuvre, Claudia
Bonnefoi, Herve
Dalenc, Florence
Jacquet, Alexandra
De Filippo, Maria R.
Babbar, Naveen
Birnbaum, Daniel
Filleron, Thomas
Le Tourneau, Christophe
André, Fabrice
- License Information
-
More Information
Article History
Received: 16 July 2018
Accepted: 21 February 2019
First Online: 22 May 2019
Change Date: 16 July 2019
Change Type: Correction
Change Details: An Amendment to this paper has been published and can be accessed via a link at the top of the paper.
Competing interests
: N.B. is an employee of Novartis. F.A. and T.B. received grants from Novartis. F.A. attended the advisory board and gave talks at events sponsored by Novartis. Gustave Roussy Hospital was compensated for these. M. Campone, F.D. and T.B. received honoraria from Novartis. The RUBY trial is funded by Clovis. The MONALEESA trials are sponsored by Novartis. J.C.S. is an employee and holds stock in AstraZeneca since September 2017. Over the past five years he has received consultancy fees from: AstraZeneca, Astex, Clovis, GSK, GamaMabs, Lilly, MSD, Mission Therapeutics, Merus, Pfizer, PharmaMar, Pierre Fabre, Roche-Genentech, Sanofi, Servier, Symphogen and Takeda. He is also a shareholder in Gritstone.
